The company will still provide interpretation-only services, but by adding in-house testing it has dramatically increased its customer base.
Inova plans to offer broad and condition-specific PGx gene panels in its specialty clinics and is negotiating with payors for reimbursement.
Admera's 50-gene PGxOne Plus assay can help predict how patients will respond to drug therapy in cardiology, psychiatry, pain management, and oncology.
The two companies said they will integrate their technologies to create a sample management and interpretation and reporting system.
The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.
The company, which is part of Opko Health's BioReference Laboratories, recently hired a new managing director, who plans to expand the firm's market and testing portfolio.
The Canadian company recently published results of a study demonstrating the utility of its pharmacogenomic testing and decision support platform.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
The researchers said that the goal was to design a model that other health care institutions could integrate in order to standardize PGx testing.
The Pharmacogenomics Clinical Annotation Tool interprets variants from sequencing or genotyping tests and generates a report to inform prescribing decisions.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.